AstraZeneca’s Lynparza has become the first drug in its class approved to treat breast cancer, after the FDA allowed it an expanded licence. The FDA approved Lynparza (olaparib) as a treatment ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

AstraZeneca’s ovarian cancer drug Lynparza is facing competition in Europe with Tesaro's rival Zejula now set for launch. Zejula (niraparib) has now gained final marketing approval from the the ...

PE: The six-year follow-up from the OlympiA trial showed a 28% reduction in the risk of death with Lynparza. How does this result compare to other treatments available for gBRCAm HER2-negative ...

Revenues increased across all segments, with sales of most of the key drugs, including Tagrisso, Fasenra, Farxiga, Lynparza and Symbicort, beating estimates. The British drugmaker said that the ...